Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21607282 | 0.84 | HCRTR2 (0.41) | DRD2HCRTR2KMT2AACACBEPHX1 | |
| SCHEMBL28458597 | 0.84 | HCRTR2 (0.41) | DRD2HCRTR2KMT2AACACBEPHX1 | |
| SCHEMBL8284744 | 0.81 | SMN1; SMN2 (0.41) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL5963740 | 0.81 | TDP1 (0.42) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL8117400 | 0.81 | TDP1 (0.42) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL21607409 | 0.81 | HCRTR2 (0.39) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL21607408 | 0.81 | HCRTR2 (0.39) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL21607699 | 0.81 | HCRTR2 (0.39) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL21607705 | 0.81 | HCRTR2 (0.39) | DRD2HCRTR2KMT2AACACBACACA | |
| SCHEMBL28532985 | 0.81 | HCRTR2 (0.39) | DRD2HCRTR2KMT2AACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | DRD2 1429/4885HCRTR2 130/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.